Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) Dividend History

Company News

• Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

  Orchestra BioMed's AVIM therapy has received FDA Breakthrough Device Designation for treating uncontrolled hypertension in patients with increased cardiovascular risk, regardless of pacemaker indication. The company is currently enrolling the BACKBEAT global pivotal study to further evaluate the safety and efficacy of AVIM therapy.

  GlobeNewswire Inc.

  Featured Companies: MDT
• Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?

  Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  Zacks Investment Research

  Featured Companies: ALKS
• Top 4 Health Care Stocks That Should Keep You Up At Night

  The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) Orchestra ...

  Benzinga

  Featured Companies: CRNX
• Why Shares of Orchestra BioMed Jumped Tuesday

  The company got approval from the FDA to go ahead with a pivotal study for a hypertension therapy.

  The Motley Fool

  Featured Companies: MDT